Verrica Pharmaceuticals
VRCA
48 hedge funds and large institutions have $96.6M invested in Verrica Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 15 increasing their positions, 17 reducing their positions, and 7 closing their positions.
1.47% less ownership
Funds ownership: 35.7% → 34.23% (-1.5%)
8% less funds holding
Funds holding: 52 → 48 (-4)
12% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 17
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
79% less capital inflows, than outflows
Capital inflows: $1.46M | Capital outflows: $6.82M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
+$339K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$221K |
| 3 |
Los Angeles Capital Management
Los Angeles,
California
|
+$201K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$138K |
| 5 |
State Street
Boston,
Massachusetts
|
+$135K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CI
Conning Inc
Hartford,
Connecticut
|
-$2.05M |
| 2 |
FI
Fosun International
Hong Kong,
China
|
-$1.17M |
| 3 |
SRAM
Spouting Rock Asset Management
Bryn Mawr,
Pennsylvania
|
-$748K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$723K |
| 5 |
Goldman Sachs
New York
|
-$531K |
VRCA Hedge Fund Activity: Q1 2020 in Review
48 of the 4,549 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q1 2020, worth a combined $96.6M — down 33% from $144M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of VRCA and 4 opened new positions — a net loss of 3 holders — while 17 trimmed existing stakes and 15 added.
The largest buyer was Kornitzer Capital Management, adding an estimated $339K. The largest seller was Conning Inc, exiting entirely with an estimated $2.05M sold.
- 48 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q1 2020, down from 52 in Q4 2019.
- Funds reported $96.6M of Verrica Pharmaceuticals stock for Q1 2020, down 33% quarter-over-quarter.
- 4 funds opened new Verrica Pharmaceuticals positions in Q1 2020 and 7 closed out, a net change of -3 holders.
- The largest Verrica Pharmaceuticals buyer in Q1 2020 was Kornitzer Capital Management, an estimated $339K added.
- The largest Verrica Pharmaceuticals seller in Q1 2020 was Conning Inc, an estimated $2.05M sold.
Based on aggregated 13F filings for Q1 2020.